Maninil 5mg tbl N120

Prescription drug

Manufacturer: Берлин-Хеми
Рецептурный препарат
манинил 5мг тбл n120
Product is available in pharmacies:
Choose a pharmacy where you would like to pick up the goods
130,00 rub.
+ 3 bonuses на карту
- +
Add to cart
All products in the order are reserved for 24 hours,
after that the order is automatically canceled
Brief information

Производитель

Берлин-Хеми

Действующее вещество

Глибенкламид

The appearance of the product may differ from the photos on the site.

General description
Источник:  РЛС

Composition

Manil 1.75

Pills1 table.
glibenclamide micronized1.75 mg
excipients: lactose monohydrate; potato starch; methylhydroxyethylcellulose; silicon dioxide colloidal; magnesium stearate; cochineal red A (dye E124) 

in glass bottles of 120 PCs.; in a pack of cardboard 1 bottle or in a blister of 10 or 20 PCs.; in a pack of cardboard 3 blisters.

Maninil 3.5

Pills1 table.
glibenclamide micronized3.5 mg
excipients: lactose monohydrate; potato starch; methylhydroxyethylcellulose; silicon dioxide colloidal; magnesium stearate; cochineal red A (dye E124) 

in glass bottles of 120 PCs.; in a pack of cardboard 1 bottle or in a blister of 10 or 20 PCs.; in a pack of cardboard 3 blisters.

Manil 5

Pills1 table.
glyburide5 mg
excipients: lactose monohydrate; magnesium stearate; potato starch; talc; gelatin; cochineal red A (dye E124) 

in glass bottles of 120 PCs.; in a pack of cardboard 1 bottle or in a blister 20 PCs.; in a pack of cardboard 1, 2, 3, 4 or 6 blisters.

CHARACTERS

Sulfonylurea derivative of the second generation.

Micronized Maninil is a high-tech, specially ground form of glibenclamide that provides an optimal pharmacokinetic and pharmacodynamic profile.

Pharmacological action

It has pancreatic and extrapancreatic effects. Pancreatic activity is manifested in the stimulation of insulin production by beta cells of the pancreas, extrapancreatic activity-in increasing the sensitivity of insulin receptors of target tissues (due to stimulation of tyrosine kinase) to insulin, suppression of gluconeogenesis and glycogenolysis in the liver.

Description of the dosage form

1.75 and 3.5 mg tablets: round, flat on both sides, pink in color, with beveled edges and one-sided risk for division.
5 mg tablets: round, flat on both sides, from pale pink to pink, with beveled edges and a notch for division.

Pharmacokinetics

Quickly (due to micronization) is absorbed in the digestive tract, which allows you to take immediately before meals. Bioavailability-100% in micronized forms.

Binding to plasma proteins-95%. T 1/2-3-10 h. Duration of action-more than 12 h. in the liver, biotransformed with the formation of inactive metabolites. Excreted by the kidneys (50%) and liver (50%). There is no cumulation.

The rate of absorption of micronized Ink is higher, it dissolves faster and is delivered to the body's tissues.

Pharmacodynamics

Reduces the risk of all complications of insulin-independent diabetes mellitus (vascular, retinopathy, nephropathy, cardiopathy) and mortality associated with diabetes mellitus.

It has a cardioprotective and antiarrhythmic effect, reduces platelet aggregation

CLINICALPHARMACOLOGY

The micronized form provides an earlier achievement of C max, the compliance of the hypoglycemic effect almost corresponds to the peak of postprandial hyperglycemia, which ensures the physiology of its effect in combination with a shortened T 1/2 , and reduces the risk of hypoglycemia. The daily requirement for glibenclamide can be reduced by 30-40%.

Indications of the drug

Type 2 diabetes mellitus (insulin-independent) with ineffective diet therapy, weight loss in obesity and sufficient physical activity.

Contraindications

Hypersensitivity (including to sulfa drugs and other sulfonylureas), diabetes mellitus type 1 (insulin dependent), decompensation of metabolism (ketoacidosis, precoma, coma), status after resection of the pancreas, severe liver disease and kidney failure, some acute conditions (for example, decompensation of carbohydrate metabolism in infectious diseases, burns, injuries or after major surgery, when is shown holding insulin), leukopenia, intestinal obstruction, gastric paresis, state, accompanied by malabsorption of food and hypoglycemia, pregnancy and lactation.

Use during pregnancy and lactation

Contraindicated during pregnancy. Breastfeeding should be stopped during treatment.

Dosage and administration

Inside, morning and evening, before eating, without chewing. The dose is set individually, depending on the severity of the disease.

Manil 1.75

The initial dose is 1/2 table., average — 2 table. per day, maximum — 3, in exceptional cases — 4 table. per day. If you need to take higher doses of the drug (up to 14 mg/day), switch to Maninil 3.5 mg.

Maninil 3.5

The initial dose is 1/2-1 table., average — 1 table. per day, maximum — 3, in exceptional cases — 4 table. per day. Daily doses up to 2 table. take usually once (in the morning), higher-divided into 2 receptions (morning and evening).

Manil 5

The initial dose is 1/2 table., average — 2 table. per day, the maximum is 3-4 tables. per day.

Three dosage forms allow you to use 20 possible dosage schemes.

Side effect

Hypoglycemia is possible (if you skip meals, overdose of the drug, with increased physical activity, as well as with heavy alcohol consumption).

From the digestive tract: sometimes-nausea, vomiting; in some cases-cholestatic jaundice, hepatitis.

From the hematopoietic system: very rarely — thrombocytopenia, granulocytopenia, erythrocytopenia (up to pancytopenia), in some cases — hemolytic anemia.

Allergic reactions: extremely rare-skin rash, fever, joint pain, proteinuria.

Other: at the beginning of treatment, a transient accommodation disorder may occur. In rare cases, photosensitivity.

Interaction

The effect is enhanced by ACE inhibitors, anabolic steroids, beta-blockers, fibrates, biguanides, chloramphenicol, cimetidine, coumarin derivatives, some antitumor drugs, pentoxifylline, phenylbutazone, reserpine, salicylates, sulfonamides, tetracyclines; weaken — acetazolamide, barbiturates, chlorpromazine, glucocorticoids, glucagon, hormonal contraceptives, phenothiazines, phenytoin, saluretics, thyroid hormones. When taken simultaneously with alcohol, both strengthening and weakening of the hypoglycemic effect is possible.

Overdose

Symptoms: hypoglycemia (acute hunger, increased sweating, body trembling, palpitations, agitation, headache, sleep disorder).

Treatment: ingestion of sugar or easily digestible carbohydrates (in mild cases), intravenous administration — 40-80 ml of 40% glucose solution, then intravenous infusion — 5-10% glucose solution (in severe cases); in/m or p/C — 1-2 mg of glucagon.

Precautionary measures

With caution, it is used for feverish syndrome, thyroid diseases (with impaired function), hypofunction of the anterior pituitary or adrenal cortex, alcoholism,in elderly patients due to the likelihood of hypoglycemia. Regular medical monitoring is required. During treatment, you should strictly follow a diet. Welcome Maninila does not replace the diet. During treatment, it is not recommended to engage in activities that require concentration and speed of psychomotor reactions, or to stay in the sun for a long time. It is necessary to correct the dose for physical and emotional overstrain, changing the diet.

Manufacturer

Berlin-Hemi AG / Menarini Group, Germany.

The appearance of the product may differ from the photos on the site.

Information about prescription drugs is for professionals only. The information provided should not be used by patients to make an independent decision on the use of the presented drugs and cannot serve as a substitute for a full-time consultation with a doctor.

A description of the active substances of the drug is provided. The scientific information provided is generalized and cannot be used to decide on the possibility of using a specific drug.

Analogs
Prescription drug
135,00 rub.
Product is available in pharmacies:
Prescription drug
151,00 rub.
Product is available in pharmacies:
Prescription drug
130,00 rub.
Product is available in pharmacies:
To the top